Rural Pharmacy Closures Accelerate, Threatening Healthcare Access for Millions of Americans

The accelerating wave of retail pharmacy closures across the United States is reshaping healthcare access, with rural communities bearing the heaviest burden. According to IQVIA查看公司主页 analysis, nearly 8,000 fewer retail pharmacies were in operation in 2025 compared to 2018, and the pace of closures has intensified—more than 2,000 pharmacies shut down in 2025 alone. Simultaneously, prescription volume per remaining pharmacy has climbed by approximately 3,000 scripts per year on average, from roughly 70,000 in 2023 to 78,000 in 2026, representing an 11.3% increase. The divergence is stark: fewer access points are being asked to serve more patients.

Rural Communities Face Disproportionate Exposure

Pharmacy density in rural areas is sparse, with rural zip codes typically containing fewer than three pharmacies on average, compared to nine in metro areas. This means each closure carries outsized consequences. When a single pharmacy closes in a metro zip code, 15% of people in that zip code received care at the pharmacy in the year prior to closure. In rural zip codes, that figure jumps to 54%.

Since 2021, the proportion of annual rural pharmacy closures has more than doubled from 4% to 9%. The accelerating rate means twice as many patients and prescriptions are being affected, with each closure in 2025 displacing as many as 3,000 patients and 35,000 prescriptions.

"The closure of a single rural pharmacy impacts a higher proportion of patients and prescriptions compared to those in metro, micro, or small towns, as there are often few or no alternative pharmacies available," the IQVIA查看公司主页 report states.

Vaccination Rates Plummet After Closures

The impact of closures is especially visible in vaccination patterns. Pharmacies serve as the site of care for one in two or more vaccinations for influenza (搜索)搜索该疾病, COVID-19 (搜索)搜索该疾病, and Respiratory Syncytial Virus (搜索)搜索该疾病 (RSV). Since the 2021 flu season, rural flu vaccine recipients who experienced a pharmacy closure were significantly more likely than metro patients to stop receiving flu vaccination in the subsequent season.

Among rural flu vaccine recipients whose pharmacy closed between 2021 and 2025, 63% to 70% of patients did not get a flu vaccine in the season after the closure. By comparison, approximately 54% of metro patients did not get a flu vaccine in the subsequent season over the same timeframe.

For rural patients who did continue vaccination by switching pharmacies, the distance burden increased sharply. The median distance between the old and new pharmacy more than quadrupled, from approximately 2.9 miles for the 2021–2022 season to 13.6 miles for the 2023–2024 season. Metro distances remained relatively stable at roughly three to four miles.

Economic Pressures Driving the Crisis

The reasons behind pharmacy closures are multifaceted. Reimbursement for prescription drugs often does not reflect the cost of acquiring and dispensing products, particularly for branded treatments, while low-margin operating models are susceptible to inflationary pressure. Pharmacy benefit manager (PBM) dynamics—including preferred networks, vertical integration, and opaque payment models—further affect whether community pharmacies remain financially viable.

"More volume at low or negative margins only adds to the constraints rather than providing relief," IQVIA查看公司主页 notes. Clinical services provided by pharmacists are also under-reimbursed or not reimbursed at all, even when those services reduce downstream healthcare utilization.

Across both branded and generic products, core dispensing has become increasingly unprofitable, with many pharmacies operating at or below breakeven. Retail has seen a 1.8% decline in generic sales growth from 2024 to 2025, while non-retail and mail channels have experienced growth of 3.3% and 10.2%, respectively.

Pharmacists' Expanding Clinical Role

The traditional view of pharmacies as medication dispensers no longer reflects their full role in healthcare delivery. Studies show pharmacist involvement in chronic disease management improves medication adherence, reduces hospital and emergency department visits, and improves outcomes. From 2019 to 2025, pharmacist prescribing for products related to diabetes (搜索)搜索该疾病, hypertension (搜索)搜索该疾病, mental health, and anticoagulation has doubled, highlighting their growing direct role in managing chronic diseases.

These conditions are among the most common and consequential health challenges in rural communities, each requiring ongoing management, monitoring, patient education, medication optimization, and adherence support.

Policy Levers for Stabilization

Stabilizing rural pharmacy access requires sustainable medication reimbursement, including cost-based payment models, fair reimbursement standards, and greater transparency in pricing. Comprehensive PBM reform is also critical, particularly policies addressing opaque reimbursement practices, network design, vertical integration, and pharmacy payment methods.

Policies must also enable pharmacies to meet community needs through expanded scope-of-practice laws, including test-and-treat authority, and by moving toward a standard-of-care model similar to other healthcare providers. Consistent insurance coverage for pharmacist-delivered clinical services as part of the medical benefit would strengthen financial sustainability while expanding access to chronic disease management and treatment of common respiratory illnesses.

Public sentiment reflects the urgency: 97% of surveyed adults reported it is important for steps to be taken to reduce the rate of pharmacy closures in the U.S.

"The question is not whether pharmacies can contribute to rural health transformation. They already do," the IQVIA查看公司主页 report concludes. "The question is whether policy, payment, and data systems will recognize that role before more communities lose it."